Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2 / Phase 3NCT01348126
Official study title

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Study summary

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDocetaxel and Combination of ganetespib and docetaxel

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 5, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2 / Phase 3

Interventional

Where is it offered?53 U.S. locations

Locations may change over time.

Who runs it?Synta Pharmaceuticals Corp.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2 / Phase 3
Sponsor
Synta Pharmaceuticals Corp.
Interventions being studied
Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • confirmed diagnosis of NSCLC
  • Stage IIIB or IV NSCLC
  • ECOG Performance Status 0 or 1
  • Prior therapy defined as 1 prior systemic therapy for advanced disease
  • measurable disease
  • Radiologic evidence of disease progression following most recent prior treatment.
  • Adequate hematologic, hepatic, renal function
Reasons someone may not be able to joinExclusion criteria
  • Active or untreated CNS metastases
  • Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
  • Serious cardiac illness or medical conditions
  • Pregnant or lactating women
  • Uncontrolled intercurrent illness

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Synta Pharmaceuticals Investigative SiteTucson, Arizona
  • Synta Pharmaceuticals Investigative SiteSanta Monica, California
  • Synta Pharmaceuticals Investigative SiteAtlanta, Georgia
  • Synta Pharmaceuticals Investigative SiteChicago, Illinois
  • Synta Pharmaceutials Investigative SiteBoston, Massachusetts
  • Synta Pharmaceuticals Investigative SiteWinston-Salem, North Carolina
  • Synta Pharmaceuticals Investigative SiteKettering, Ohio
  • Synta Pharmaceuticals Investigative SitePortland, Oregon
  • Synta Pharmaceuticals Investigative SiteBrussels
  • Synta Pharmaceuticals Investigative SiteJette
  • Synta Pharmaceuticals Investigative SiteYvoir
  • Synta Pharmaceuticals Investigative SiteBanja Luka

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 5, 2015. Always confirm current availability with the study team.

View original record ↗